Eye-care drugmaker Alcon said on Wednesday that the U.S. Food and Drug Administration has approved its treatment for dry eye disease (DED).

Alcon, a global eye care company known for products such as Systane and GenTeal Tears, plans to launch Tryptyr in the U.S. market in the third quarter of 2025. International rollouts are expected to ...

Six years after being spun out from Novartis and becoming a public company, eye care specialist Alcon has gained its first ...

The US FDA has cleared Grifols' investigational new drug (IND) application to commence a Phase II trial of GRF312 Ophthalmic ...

Melbourne biotech PolyActiva says it hopes to be the next Cochlear by selling its eye drug dispensing system to millions ...

Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms ...

The FDA cleared an investigational new drug application for a phase 2 trial of GRF312 ophthalmic solution, an immunoglobulin ...

Dry eye syndrome, a condition affecting millions of Americans each year, continues to present a frustrating challenge for ...

It's as if she's squinting through a smoke-filled room. But it's Charisse Brown's eye condition, glaucoma, that diminishes her vision. Brown, 38, has worked all her adult life, with a personal policy ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

A new randomized controlled trial reveals that topical timolol significantly improves the appearance of post-mammoplasty ...